CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928668
NCT00928668Phase 2Completed
CompareCT.gov

Randomised, Double-Blind, Placebo-Controlled, 5-Way Cross-Over Study to Assess the Efficacy (Bronchoprotection) and Safety of a Single Dose of Orally Inhaled BI 1744 CL (2, 5, 10 and 20ug) in Patients With Intermittent Asthma

Boehringer Ingelheim·interventional·Posted Jun 26, 2009·Updated Jul 1, 2014

In Brief

A Phase 2 clinical trial evaluating Placebo and Olodaterol (BI1744CL) for Asthma. Completed, enrolled 32 participants across 4 sites.

Detailed Summary

The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with intermittent asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2009
Enrollment StartJan 1, 2006
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.0 years ago

Interventions

Placebodrug

Placebo device for comparison

Olodaterol (BI1744CL)drug

Olodaterol comparison of low, medium low, medium high and high doses

Olodaterol (BI1744CL)drug

Olodaterol comparison of low, medium low, medium high and high doses

Olodaterol (BI1744CL)drug

Olodaterol comparison of low, medium low, medium high and high doses

Olodaterol (BI1744CL)drug

Olodaterol comparison of low, medium low, medium high and high doses